Bioadaptives (BDPT) Common Equity (2019 - 2025)
Historic Common Equity for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$1.5 million.
- Bioadaptives' Common Equity rose 1884.12% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year increase of 1884.12%. This contributed to the annual value of -$1.5 million for FY2024, which is 1109.62% up from last year.
- Per Bioadaptives' latest filing, its Common Equity stood at -$1.5 million for Q3 2025, which was up 1884.12% from -$1.1 million recorded in Q2 2025.
- Bioadaptives' 5-year Common Equity high stood at -$1.0 million for Q1 2021, and its period low was -$1.9 million during Q2 2024.
- Moreover, its 5-year median value for Common Equity was -$1.5 million (2025), whereas its average is -$1.5 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 5755.68% in 2024, then skyrocketed by 4092.26% in 2025.
- Quarter analysis of 5 years shows Bioadaptives' Common Equity stood at -$1.1 million in 2021, then tumbled by 32.79% to -$1.5 million in 2022, then dropped by 13.44% to -$1.6 million in 2023, then increased by 11.1% to -$1.5 million in 2024, then fell by 0.09% to -$1.5 million in 2025.
- Its Common Equity was -$1.5 million in Q3 2025, compared to -$1.1 million in Q2 2025 and -$1.6 million in Q1 2025.